Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price traded down 10.4% during trading on Wednesday . The company traded as low as GBX 23 and last traded at GBX 23.75. 3,199,308 shares changed hands during trading, an increase of 64% from the average session volume of 1,951,172 shares. The stock had previously closed at GBX 26.50.
Scancell Stock Up 4.8%
The business has a fifty day moving average of GBX 14.41 and a 200 day moving average of GBX 12.42. The company has a market capitalization of £228.31 million, a PE ratio of -40.00 and a beta of 0.57. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Read More
- Five stocks we like better than Scancell
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
